Literature DB >> 12154050

Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer.

Daniel R Rhodes1, Terrence R Barrette, Mark A Rubin, Debashis Ghosh, Arul M Chinnaiyan.   

Abstract

The increasing availability and maturity of DNA microarray technology has led to an explosion of cancer profiling studies. To extract maximum value from the accumulating mass of publicly available cancer gene expression data, methods are needed to evaluate, integrate, and intervalidate multiple datasets. Here we demonstrate a statistical model for performing meta-analysis of independent microarray datasets. Implementation of this model revealed that four prostate cancer gene expression datasets shared significantly similar results, independent of the method and technology used (i.e., spotted cDNA versus oligonucleotide). This interstudy cross-validation approach generated a cohort of genes that were consistently and significantly dysregulated in prostate cancer. Bioinformatic investigation of these genes revealed a synchronous network of transcriptional regulation in the polyamine and purine biosynthesis pathways. Beyond the specific implications for prostate cancer, this work establishes a much-needed model for the evaluation, cross-validation, and comparison of multiple cancer profiling studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12154050

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  260 in total

1.  An empirical Bayes' approach to joint analysis of multiple microarray gene expression studies.

Authors:  Lingyan Ruan; Ming Yuan
Journal:  Biometrics       Date:  2011-04-22       Impact factor: 2.571

2.  Statistical issues and methods for meta-analysis of microarray data: a case study in prostate cancer.

Authors:  Debashis Ghosh; Terrence R Barette; Dan Rhodes; Arul M Chinnaiyan
Journal:  Funct Integr Genomics       Date:  2003-07-22       Impact factor: 3.410

3.  Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression.

Authors:  Daniel R Rhodes; Jianjun Yu; K Shanker; Nandan Deshpande; Radhika Varambally; Debashis Ghosh; Terrence Barrette; Akhilesh Pandey; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-07       Impact factor: 11.205

4.  CONFAC: automated application of comparative genomic promoter analysis to DNA microarray datasets.

Authors:  Suresh Karanam; Carlos S Moreno
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

5.  The genomic response of skeletal muscle to methylprednisolone using microarrays: tailoring data mining to the structure of the pharmacogenomic time series.

Authors:  Richard R Almon; Debra C DuBois; William H Piel; William J Jusko
Journal:  Pharmacogenomics       Date:  2004-07       Impact factor: 2.533

6.  Coexpression analysis of human genes across many microarray data sets.

Authors:  Homin K Lee; Amy K Hsu; Jon Sajdak; Jie Qin; Paul Pavlidis
Journal:  Genome Res       Date:  2004-06       Impact factor: 9.043

7.  Assumption weighting for incorporating heterogeneity into meta-analysis of genomic data.

Authors:  Yihan Li; Debashis Ghosh
Journal:  Bioinformatics       Date:  2012-01-27       Impact factor: 6.937

Review 8.  [Prostate carcinoma: vaccination as a new option for treatment].

Authors:  J Bedke; C Gouttefangeas; A Stenzl
Journal:  Urologe A       Date:  2012-01       Impact factor: 0.639

9.  Inter-individual differences in response to dietary intervention: integrating omics platforms towards personalised dietary recommendations.

Authors:  Johanna W Lampe; Sandi L Navarro; Meredith A J Hullar; Ali Shojaie
Journal:  Proc Nutr Soc       Date:  2013-02-06       Impact factor: 6.297

10.  In silico analysis identifies CRISP3 as a potential peripheral blood biomarker for multiple myeloma: From data modeling to validation with RT-PCR.

Authors:  Dong Leng; Ran Miao; Xiaoxi Huang; Ying Wang
Journal:  Oncol Lett       Date:  2018-02-06       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.